Skip to main content

JDRF has now rebranded to Breakthrough T1D.
Our name has changed, our mission has not.

Research partnerships

Partnership funding autoimmune research now has over 10 members

Myaware, the only charity in the UK focusing on people affected by myasthenia, is the latest organisation to join Connect Immune Research.
Breakthrough T1D profile picture
Kate Lawton 18 January 2023

Welcoming Myaware

Myaware, the only charity in the UK focusing on people affected by myasthenia, is the latest organisation to join Connect Immune Research. Growing the pool of experts dedicated to finding a root cause of auto immune conditions accelerates us towards innovative new ways of treating autoimmunity.

Connect Immune Research is a revolutionary partnership of organisations that research autoimmune conditions, where the body’s immune system attacks its own cells rather than viruses and bacteria. The initiative pools resources from the member organisations to fund vital research into the overlapping biology of autoimmune conditions. The more organisations we have working together, the closer we’ll be to achieving our common goal of understanding and treating the causes of autoimmunity.

Who are the current partners?

JDRF UK, Versus Arthritis, the MS Society and the British Society for Immunology founded Connect Immune Research with the mission to find shared causes of autoimmune conditions. Having recruited seven new members, the partnership now stands at 11 autoimmune research organisations, demonstrating the value the research community sees in working beyond individual conditions to tackle autoimmunity.

Dr David Coutts, Senior Research Manager at the MS Society, said: “We’re delighted to welcome myaware to our Connect Immune Research partnership. Around four million people in the UK have an autoimmune condition like multiple sclerosis, rheumatoid arthritis or type 1 diabetes, and up to a third of people live with more than one of these conditions at once. Research into autoimmune conditions often only looks at a single condition, like MS, or a single organ, like the brain. We believe by linking up research and looking for common threads, we’ll be better able to treat these conditions in the future.

“As well as speeding up research into new treatments for millions of people with autoimmune conditions, the approach could also dramatically reduce costs. We want autoimmunity to be recognised as a distinct area of research science, alongside the likes of cancer, infectious disease and dementia.”

What is myasthenia?

Myasthenia is a group of conditions, most of which are autoimmune, causing weakness in the body’s voluntary muscles and the muscles that control breathing.

Myaware, whose tagline fighting myasthenia together aligns closely with the values of Connect Immune Research, are the latest charity to join the partnership.

The wide range of organisations now united to tackle autoimmunity expands our portfolio of expertise and boosts our research prospects. Ultimately, this will help us gain crucial insights about autoimmunity that could lead to new treatments for people living with autoimmune conditions.

Related news

Read more
Grid of unbranded vials of insulin with purple tops
Research
27 June 2025

Update on NovoRapid PumpCart supply for YpsoPump users

We’re aware of growing concern around insulin supply in the UK, and we want to reassure our community that this is not a general insulin shortage. There is no need to change the type of insulin you use.

Read more
Two young people sat in a park, with type 1 diabetes continuous glucose monitor visible on their arms
Breakthrough T1D
20 June 2025

Warning issued for Dexcom G6 users as Android 16 update causes compatibility issues

If you use the Dexcom G6 app on your Android smartphone, the newest Android 16 operating system may disrupt how the app functions.

Read more
Young man and woman with type 1 diabetes using diabetes technology
News
21 May 2025

mylife CamAPS FX app now available on iOS across the UK

People living with type 1 diabetes (T1D) across the UK now have more choice in how to manage their condition, with the mylife CamAPS FX app now available on iPhones.

Read more
Young man and woman with type 1 diabetes using diabetes technology
News
25 March 2025

Novo Nordisk to discontinue Levemir insulin by end of 2026

Novo Nordisk will stop producing Levemir insulin next year but there are plans in place to help you transition to an alternative.